Premium
Derivation of Canine Induced Pluripotent Stem Cells
Author(s) -
Baird AEG,
Barsby T,
Guest DJ
Publication year - 2015
Publication title -
reproduction in domestic animals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 66
eISSN - 1439-0531
pISSN - 0936-6768
DOI - 10.1111/rda.12562
Subject(s) - induced pluripotent stem cell , reprogramming , germ layer , regenerative medicine , biology , mesenchymal stem cell , ectoderm , stem cell , mesoderm , microbiology and biotechnology , endoderm , embryonic stem cell , genetics , cell , gene
Contents Dogs and humans have many inherited genetic diseases in common and conditions that are increasingly prevalent in humans also occur naturally in dogs. The use of dogs for the experimental and clinical testing of stem cell and regenerative medicine products would benefit canine health and welfare and provide relevant animal models for the translation of therapies to the human field. Induced pluripotent stem cells ( iPSC s) have the capacity to turn into all cells of the body and therefore have the potential to provide cells for therapeutic use and for disease modelling. The objective of this study was to derive and characterize iPSC s from karyotypically abnormal adult canine cells. Aneuploid adipose‐derived mesenchymal stromal cells ( A d MSC s) from an adult female W eimeraner were re‐programmed into iPSC s via overexpression of four human pluripotency factors ( O ct 4, S ox2, K lf4 and c‐myc) using retroviral vectors. The iPSC s showed similarity to human ESC s with regard to morphology, pluripotency marker expression and the ability to differentiate into derivatives of all three germ layers in vitro (endoderm, ectoderm and mesoderm). The iPSC s also demonstrated silencing of the viral transgenes and re‐activation of the silent X chromosome, suggesting full reprogramming had occurred. The levels of aneuploidy observed in the A d MSC s were maintained in the iPSC s. This finding demonstrates the potential for generating canine induced pluripotent stem cells for use as disease models in addition to regenerative medicine and pharmaceutical testing.